Merck And Ridgeback Announce U.K. Government To Purchase Additional 1.75 Million Courses Of Molnupiravir
Published by
The Street
The Street
By Business Wire Merck (MRK) – Get Merck & Co., Inc. Report, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today announced that the United Kingdom Government will purchase an additional 1.75 million patient courses of molnupiravir (MK-4482), an investigational oral antiviral COVID-19 medicine. In the U.K., LAGEVRIO ® is the planned trademark for molnupiravir; the trademark for molnupiravir in other countries has not been approved. With this additional procurement agreement, which follows a previously announced agreement for 480,000 courses of treatment, the U…
